PHARMACY UPDATE
New advances in the management of juvenile idiopathic arthritis—2: The era of biologicals
1 Institute of Child Health, Alder Hey Children's NHS Foundation Trust, University of Liverpool, Liverpool, UK
2 Department of Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
Correspondence to:
Correspondence to Dr Michael W Beresford, Institute of Child Health, University of Liverpool, Alder Hey Children's NHS Foundation Trust, Eaton Road, Liverpool L12 2AP, UK; m.w.beresford{at}liverpool.ac.uk
Juvenile idiopathic arthritis (JIA) is the most common paediatric rheumatic disease with significant long-term morbidity and mortality. Major advances have taken place in recent years in our understanding and the evidence base of JIA.
The advent of biological therapies has opened a major new era in the medical management of JIA with recent trials published of etanercept, infliximab, adalimumab, abatacept, tocilizumab and anakinra.
National and international collaborative clinical and research networks are ideally placed to enable future advances in the management of JIA and all paediatric rheumatic disorders.
This review follows on from Part 1 of a review of recent advances in non-biological therapies in JIA, and focuses on the significant new advances in biological therapies in managing JIA.
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.



